Research Analysts Issue Forecasts for SPRY FY2025 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for ARS Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($1.20) for the year. Cantor Fitzgerald has a “Overweight” rating and a $30.00 price objective on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.58) per share.

SPRY has been the topic of a number of other research reports. Raymond James boosted their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. Leerink Partners boosted their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $26.00.

ARS Pharmaceuticals Trading Up 0.5 %

NASDAQ SPRY opened at $13.55 on Thursday. The stock has a market cap of $1.32 billion, a P/E ratio of -26.57 and a beta of 0.96. The company’s fifty day simple moving average is $12.46 and its 200-day simple moving average is $12.93. ARS Pharmaceuticals has a 52 week low of $6.13 and a 52 week high of $18.51.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers boosted its stake in ARS Pharmaceuticals by 78.0% in the second quarter. Rhumbline Advisers now owns 65,942 shares of the company’s stock valued at $561,000 after acquiring an additional 28,888 shares during the period. American Century Companies Inc. lifted its holdings in shares of ARS Pharmaceuticals by 20.7% in the 2nd quarter. American Century Companies Inc. now owns 97,803 shares of the company’s stock worth $832,000 after purchasing an additional 16,761 shares during the last quarter. Renaissance Technologies LLC boosted its position in ARS Pharmaceuticals by 884.9% during the 2nd quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock valued at $1,056,000 after purchasing an additional 111,500 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of ARS Pharmaceuticals in the 2nd quarter worth about $180,000. Finally, Creative Planning raised its holdings in shares of ARS Pharmaceuticals by 7.0% during the third quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after buying an additional 2,307 shares during the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Brian Dorsey sold 25,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the transaction, the chief operating officer now owns 6,024 shares in the company, valued at approximately $74,095.20. This trade represents a 80.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Laura Shawver sold 14,772 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $13.75, for a total value of $203,115.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,892,257.50. This represents a 6.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,095,558 shares of company stock valued at $16,853,686 in the last ninety days. Corporate insiders own 40.10% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.